Full Prescribing Information
Important Safety Information
For Patients

Press Releases

Professional > Resources > Press Releases


CMS Grants Vistogard® New Technology Add-on Payment Status Effective 1 October 2016

West Conshohocken, PA, BTG plc (LSE: BTG), the specialist healthcare company, today announces that Centers for Medicare and Medicaid Services (CMS) has approved a New Technology Add-on Payment (NTAP) for Vistogard®, effective 1 October 2016. The CMS decision means that Medicare will pay up to...



BTG Announces Presentation of New Vistogard® (uridine triacetate) Data at American Society o...

London, UK, 20 January 2016: BTG plc (LSE: BTG) announced today the presentation of new data for Vistogard® (uridine triacetate) oral granules at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) 2016 (January 21-23). Vistogard® is the first and only a...



BTG Announces FDA Approval of VISTOGARD® (Uridine Triacetate) as Antidote to Overdose and Ea...

London, UK, December 11, 2015: BTG plc (LSE: BTG) announced today that the United States Food and Drug Administration (FDA) has approved Wellstat Therapeutics’ VISTOGARD® (uridine triacetate) as the first and only drug to treat patients following an overdose of chemotherapy drugs 5-fluo...



Wellstat Announces FDA Approval of VISTOGARD® (Uridine Triacetate), the First Antidote to Tr...

Rockville<span style="line-height: 20.8px;">, MD – December 11, 2015 – Wellstat Therapeutics Corporation announced today that the US Food and Drug Administration (FDA) has approved VISTOGARD® (uridine triacetate) as the first and only antidote for emergency treatme...